SETD2 and cancer: In line, detailed survival analysis in our cohort indicated significantly worse cancer-specific survival probability for patients with metastases harbouring multiple somatic drivers and VHL wildtype alleles compared to PBRM1, SETD2, and VHL monodrivers (p (logrank) = 0.03) (Figure 2D).